Cao Yunshan, Geng Chao, Li Yahong, Zhang Yan
Department of Cardiology, Gansu Provincial Hospital, Lanzhou, China.
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Front Pharmacol. 2021 Jul 8;12:671589. doi: 10.3389/fphar.2021.671589. eCollection 2021.
Pulmonary thromboembolism (PTE) is the third leading cause of death in cardiovascular diseases. PTE is believed to be caused by thrombi detached from deep veins of lower extremities. The thrombi travel with systemic circulation to the lung and block pulmonary arteries, leading to sudden disruption of hemodynamics and blood gas exchange. However, this concept has recently been challenged by accumulating evidence demonstrating that de novo thrombosis may be formed in pulmonary arteries without deep venous thrombosis. On the other hand, chronic thromboembolic pulmonary hypertension (CTEPH), a subtype of pulmonary hypertension, could have different pathogenesis than traditional PTE. Therefore, this article summarized and compared the risk factors, the common and specific pathogenic mechanisms underlying PTE, in situ pulmonary artery thrombosis, and CTEPH at molecular and cellular levels, and suggested the therapeutic strategies to these diseases, aiming to facilitate understanding of pathogenesis, differential diagnosis, and precision therapeutics of the three pulmonary artery thrombotic diseases.
肺血栓栓塞症(PTE)是心血管疾病中第三大致死原因。PTE 被认为是由下肢深静脉脱落的血栓引起的。这些血栓随体循环至肺部并阻塞肺动脉,导致血流动力学和血气交换突然中断。然而,最近越来越多的证据对这一概念提出了挑战,这些证据表明,在没有深静脉血栓形成的情况下,肺动脉中可能会形成新的血栓。另一方面,慢性血栓栓塞性肺动脉高压(CTEPH)作为肺动脉高压的一种亚型,其发病机制可能与传统的 PTE 不同。因此,本文在分子和细胞水平上总结并比较了 PTE、原位肺动脉血栓形成和 CTEPH 的危险因素、共同和特定的致病机制,并提出了针对这些疾病的治疗策略,旨在促进对这三种肺动脉血栓性疾病的发病机制、鉴别诊断和精准治疗的理解。